Phastar hosted a webinar exploring regulatory expectations for Bayesian methods across the FDA, CDE, and EMA on 24 September 2026.
Published
Signal category
Presence & Recognition
Quote
“New Webinar: Understanding Regulatory Expectations for Bayesian Methods Across the FDA, CDE, and EMA. As Bayesian methods become increasingly important in clinical development, understanding regulatory expectations across different regions is critical.”
— Phastar team
Company
Phastar
Bringing data to life
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 374 employees
Phastar is an award-winning specialist biometrics and data science CRO, trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, it brings expertise, precision, and pace to every trial – because behind every data point is a patient waiting for treatment. Phastar doesn’t just deliver high-quality clinical trial data. It partners with clients to turn complexity into clarity. Leveraging technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, it accelerates regulatory approvals, ensures compliance with global standards and mitigates risk. Phastar has a proven track record in transforming complex data into clear, actionable intelligence, empowering its partners to accelerate drug development. With scalable, tailored solutions, it expedites trials – bringing life-changing therapies to patients faster.
Founded 2007